Search clinical trials for: oxi4503

Total 4 results

Mateon Therapeutics
Cancer Research UK

Completed

Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

Solid Tumors

United Kingdom
Mateon Therapeutics

Unknown

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

United States
Mateon Therapeutics

Completed

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden (OXi4503)

Neoplasm Metastasis

Australia
University of Florida
The Leukemia and Lymphoma Society

Terminated

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

Myelodysplastic Syndromes | Leukemia, Myelogenous, Acute

United States

3

Subscribe